According to filings with the U.S. Securities and Exchange Commission, Forus has raised $160 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the current round of funding include: Thrive Capital, General Catalyst, Accel, Bain Capital Ventures (BCV), Redpoint, BoxGroup, and Pear VC.

About Forus
Forus is a healthcare technology company that uses AI to automate every step from prescription to affordable medication access, so patients can start therapy faster at no cost to doctors or patients. Its AI-powered platform is embedded directly into physician workflows and handles complex tasks such as prior authorizations, appeal letters, enrollment forms, benefit verifications, affordability programs, specialty pharmacy coordination, pharmacy routing, and ongoing patient communication across every drug, payer, and pharmacy in the country. By abstracting the complexity of insurance, financial assistance, and supply chain logistics, Forus enables clinicians to confidently prescribe the most effective treatments while patients who once waited weeks or months can begin therapy in days. The company is building a first-of-its-kind network that connects doctors, pharmacies, payers, and biopharma, giving life sciences companies unmatched insight into how medicines perform in the real world and helping them design better research, launch new drugs more effectively, and invest in harder-to-treat conditions. Based in New Yorks SoHo neighborhood, Forus describes itself as a generational opportunity with exceptional product market fit and rapid organic adoption, positioning the company as a foundational infrastructure player in how modern medicine reaches society.

To learn more, visit https://www.forus.com/
Linkedin: https://www.linkedin.com/company/forushq/

Contact:
Sahir Jaggi, Chief Executive Officer
https://www.linkedin.com/in/sahirj/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.